Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Aliment Pharmacol Ther ; 47(7): 966-979, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29388229

ABSTRACT

BACKGROUND: Endoscopic band ligation (EBL) is used for primary (PP) and secondary prophylaxis (SP) of variceal bleeding. Current guidelines recommend combined use of non-selective beta-blockers (NSBBs) and EBL for SP, while in PP either NSBB or EBL should be used. AIM: To assess (re-)bleeding rates and mortality in cirrhotic patients receiving EBL for PP or SP for variceal bleeding. METHODS: (Re-)bleeding rates and mortality were retrospectively assessed with and without concomitant NSBB therapy after first EBL in PP and SP. RESULTS: Seven hundred and sixty-six patients with oesophageal varices underwent EBL from 01/2005 to 06/2015. Among the 284 patients undergoing EBL for PP, n = 101 (35.6%) received EBL only, while n = 180 (63.4%) received EBL + NSBBs. In 482 patients on SP, n = 163 (33.8%) received EBL only, while n = 299 (62%) received EBL + NSBBs. In PP, concomitant NSBB therapy neither decreased bleeding rates (log-rank: P = 0.353) nor mortality (log-rank: P = 0.497) as compared to EBL alone. In SP, similar re-bleeding rates were documented in EBL + NSBB vs EBL alone (log-rank: P = 0.247). However, EBL + NSBB resulted in a significantly lower mortality rate (log-rank: P<0.001). A decreased risk of death with EBL + NSBB in SP (hazard ratio, HR: 0.50; P<0.001) but not of rebleeding, transplantation or further decompensation was confirmed by competing risk analysis. Overall NSBB intake reduced 6-months mortality (HR: 0.53, P = 0.008) in SP, which was most pronounced in patients without severe/refractory ascites (HR: 0.37; P = 0.001) but not observed in patients with severe/refractory ascites (HR: 0.80; P = 0.567). CONCLUSIONS: EBL alone seems sufficient for PP of variceal bleeding. In SP, the addition of NSBB to EBL was associated with an improved survival within the first 6 months after EBL.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Endoscopy, Gastrointestinal/methods , Esophageal and Gastric Varices/mortality , Esophageal and Gastric Varices/therapy , Gastrointestinal Hemorrhage/mortality , Gastrointestinal Hemorrhage/therapy , Adult , Aged , Chemoprevention/methods , Combined Modality Therapy , Esophageal and Gastric Varices/complications , Esophageal and Gastric Varices/drug therapy , Female , Gastrointestinal Hemorrhage/drug therapy , Gastrointestinal Hemorrhage/etiology , Humans , Ligation , Liver Cirrhosis/drug therapy , Middle Aged , Primary Prevention/methods , Retrospective Studies , Secondary Prevention/methods , Survival Analysis , Treatment Outcome
2.
Clin Microbiol Infect ; 24(3): 267-272, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28669844

ABSTRACT

OBJECTIVES: We report on a large prospective, multicentre clinical investigation on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori. METHODS: Therapy-naive patients (n = 2004) who had undergone routine diagnostic gastroscopy were prospectively included from all geographic regions of Austria. Gastric biopsy samples were collected separately from antrum and corpus. Samples were analysed by histopathology and real-time PCR for genotypic resistance to clarithromycin and quinolones. Clinical and demographic information was analysed in relation to resistance patterns. RESULTS: H. pylori infection was detected in 514 (26%) of 2004 patients by histopathology and confirmed in 465 (90%) of 514 patients by real-time PCR. PCR results were discordant for antrum and corpus in 27 (5%) of 514 patients, indicating inhomogeneous infections. Clarithromycin resistance rates were 17% (77/448) and 19% (84/455), and quinolone resistance rates were 12% (37/310) and 10% (32/334) in antrum and corpus samples, respectively. Combination of test results per patient yielded resistance rates of 21% (98/465) and 13% (50/383) for clarithromycin and quinolones, respectively. Overall, infection with both sensitive and resistant H. pylori was detected in 65 (14%) of 465 patients. CONCLUSIONS: Anatomically inhomogeneous infection with different, multiple H. pylori strains is common. Prospective clinical study design, collection of samples from multiple sites and microbiologic methods that allow the detection of coinfections are mandatory for collection of reliable data on antimicrobial resistance patterns in representative patient populations. (ClinicalTrials.gov identifier: NCT02925091).


Subject(s)
Drug Resistance, Bacterial , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Helicobacter pylori/genetics , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/pharmacology , Austria , Biopsy , Clarithromycin/pharmacology , Female , Gastric Mucosa/microbiology , Gastric Mucosa/pathology , Genes, Bacterial , Genetic Variation , Helicobacter pylori/isolation & purification , Histocytochemistry , Humans , Male , Middle Aged , Prospective Studies , Quinolones/pharmacology , Real-Time Polymerase Chain Reaction , Young Adult
3.
Aliment Pharmacol Ther ; 34(8): 949-59, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21883324

ABSTRACT

BACKGROUND: Sorafenib is the new reference standard for patients with advanced hepatocellular carcinoma (HCC). AIM: To identify prognostic factors in sorafenib-treated HCC patients and to evaluate outcomes with respect to liver function. METHODS: In this retrospective study, 148 HCC patients received sorafenib 400 mg b.d. across 11 Austrian institutions. Seventy-eight HCC patients who received best supportive care (BSC) in the pre-sorafenib era served as a control. RESULTS: In sorafenib-treated patients, low baseline α-fetoprotein, low Child-Pugh (CP) score, compensated cirrhosis, and low baseline aspartate aminotransferase (AST) were associated with significantly longer overall survival (OS) on univariate analysis. CP score and baseline AST remained independent prognostic factors on multivariate analysis. In patients with Barcelona Clinic liver Cancer (BCLC) stage B or C HCC (sorafenib: n = 139; BSC: n = 39), CP-A patients had a median OS of 11.3 (sorafenib [n = 76]) vs. 6.4 (BSC [n = 17]) months (P = 0.010), and CP-B patients had a median OS of 5.5 (sorafenib [n = 55]) vs. 1.9 (BSC [n = 22]) months (P = 0.021). In the sorafenib group, median OS according to baseline AST was 11.8 (<100 U/L [n = 58]) vs. 3.9 (≥100 U/L [n = 15]) months for CP-A patients (P = 0.127), and 6.5 (<100 U/L [n = 33]) vs. 2.1 (≥100 U/L [n = 21]) months for CP-B patients (P = 0.011). There was no survival difference between sorafenib and BSC in patients with BCLC stage D HCC (1.5 vs. 1.4 months; P = 0.116). CONCLUSIONS: Sorafenib was associated with improved survival in both CP-A and CP-B patients. In CP-B patients, baseline AST may be helpful in determining which patients are most likely to benefit from sorafenib.


Subject(s)
Antineoplastic Agents/therapeutic use , Benzenesulfonates/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Pyridines/therapeutic use , Administration, Oral , Aged , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/physiopathology , Female , Humans , Liver Neoplasms/mortality , Liver Neoplasms/physiopathology , Magnetic Resonance Imaging , Male , Middle Aged , Niacinamide/analogs & derivatives , Phenylurea Compounds , Prognosis , Retrospective Studies , Severity of Illness Index , Sorafenib , Statistics as Topic , Survival Rate , Tomography, X-Ray Computed
4.
Aliment Pharmacol Ther ; 32(6): 763-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20629977

ABSTRACT

BACKGROUND: The PI3K/Akt/mTOR signal pathway is involved in hepatocarcinogenesis. Rapamycin (=sirolimus), a specific mTOR inhibitor, leads to G(1) arrest of many malignant cell lines and currently, analogues of rapamycin are being investigated as a cancer chemotherapeutic adjuvant. AIM: To study the toxicity and tolerability of rapamycin therapy in patients with advanced hepatocellular carcinoma (HCC). METHODS: Between June 2005 and February 2007, patients with advanced HCC, not eligible for any established therapy, were included in the study. RESULTS: Eighteen patients (F/M: 5/13) with compensated liver cirrhosis (Child A n = 11, Child B n = 5, Child C n = 2) and histologically proven HCC were included in this study. According to the BCLC staging system, most of the patients enrolled had an advanced HCC: BCLC stage B: n = 2, Barcelona Clinic Liver-Cancer (BCLC) stage C: n = 14, BCLC stage D: n = 2. Overall, therapy with rapamycin was well tolerated. Most common toxicities were thrombocytopaenia and anaemia. We did not observe any partial or complete tumour response. At 3 months, two patients had stable disease and at 6 months, all patients had progressed. The median overall survival was 5.27 months, median time to progression was 3 months. CONCLUSION: Rapamycin is well tolerated in patients with advanced HCC, but only minimally effective.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Immunosuppressive Agents/therapeutic use , Liver Cirrhosis/drug therapy , Liver Neoplasms/drug therapy , Sirolimus/therapeutic use , Aged , Aged, 80 and over , Disease Progression , Female , Humans , Male , Middle Aged , Pilot Projects , Treatment Outcome
5.
Digestion ; 74(3-4): 169-73, 2006.
Article in English | MEDLINE | ID: mdl-17341849

ABSTRACT

We report a case of graft versus host disease after liver transplantation in which the diagnosis was made by short tandem repeat analysis. A retrospective analysis using a bone marrow sample showed the presence of chimerism already at a time when the characteristic full clinical picture of graft versus host disease had not yet developed, opening the way for the early diagnosis and treatment.


Subject(s)
Graft vs Host Disease/diagnosis , Liver Cirrhosis/genetics , Liver Cirrhosis/surgery , Liver Transplantation/adverse effects , Minisatellite Repeats , Aged , Chimerism , Follow-Up Studies , Graft Survival , Graft vs Host Disease/drug therapy , Graft vs Host Disease/genetics , Humans , Immunosuppressive Agents/therapeutic use , Liver Transplantation/methods , Male , Polymorphism, Genetic , Risk Assessment , Transplantation Chimera/genetics , Transplantation, Homologous , Treatment Outcome
6.
Gut ; 48(1): 103-9, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11115830

ABSTRACT

BACKGROUND AND AIMS: We investigated the influence of baseline characteristics of patients with hepatocellular carcinoma (HCC) on prognosis and developed a multivariate Cox model predicting survival. All patients were from Central Europe. METHODS: All 245 patients seen at the Department of Gastroenterology and Hepatology at the University of Vienna, Austria, from July 1991 to March 1998 were included in this retrospective study. Nineteen different clinical characteristics and survival time from date of diagnosis were noted. Factors determining survival time were analysed by univariate and multivariate analysis using Cox proportional hazard regression models and a new classification model was constructed. The validity of this model was tested on an independent group of 89 patients, seen from April 1998 to September 1999. RESULTS: Median survival in patients with HCC was 8.0 months. In a multivariate analysis bilirubin (>2 mg/dl), portal vein thrombosis, prothrombin time (<70%), alpha fetoprotein (>180 microg/l), tumour mass >50%, and enlarged lymph nodes were independent predictors of survival. A newly constructed Cox proportional hazard model (Vienna survival model for HCC=VISUM-HCC) identified three disease stages with different durations of survival (median survival stage 1, 15.2 months; stage 2, 7.2 months; and stage 3, 2.6 months; p=0.00001). Applying the VISUM-HCC survival model to patients in Okuda stage 2 identified subgroups with an excellent and very poor prognosis for which different treatment modalities should be offered. CONCLUSIONS: Our patients with HCC had a poor median survival of eight months. Six easily measurable clinical variables were significant predictors of survival in patients with HCC. The new VISUM-HCC survival model may be useful for stratifying patients with HCC for various clinical treatment modalities.


Subject(s)
Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Aged , Austria/epidemiology , Bilirubin/analysis , Carcinoma, Hepatocellular/complications , Female , Humans , Liver Neoplasms/complications , Lymph Nodes/pathology , Male , Middle Aged , Portal Vein , Prognosis , Proportional Hazards Models , Prothrombin Time , Retrospective Studies , Survival Rate , Thrombosis/complications , alpha-Fetoproteins/analysis
8.
Eur J Gastroenterol Hepatol ; 12(8): 941-8, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10958223

ABSTRACT

BACKGROUND AND AIMS: The aetiology of chronic liver disease leading to hepatocellular carcinoma (HCC) and the clinical characteristics at the time of presentation vary considerably among different parts of the world and over time. The number of patients seen at our institution has increased as compared to a period 20 years earlier. We investigated baseline characteristics of patients with hepatocellular carcinoma such as cirrhosis, hepatitis virus markers, age at presentation and stage of the tumour in an area with low prevalence of viral hepatitis. METHODS: All 245 patients seen at the Department of Gastroenterology and Hepatology at the University of Vienna, Austria, from July 1991 to March 1998 were included in this retrospective study, and 19 different clinical characteristics were studied. RESULTS: The median age at detection of HCC was 63.3 years, and alcoholic liver disease (35.1%) and hepatitis C virus (HCV) infection (36.7%) were the most frequent underlying diseases. Both chronic alcoholism and HCV infection as risk factors were present in 6.9% of the patients. Liver cirrhosis was present in 86.5%. At the time of diagnosis, 43.5% had multi-nodular tumours. Of the remaining patients with a single nodule, only 10% had HCC < or =2 cm. Most of our patients presented at a late stage of the disease (TNM stage 3 29.4%, TNM stage 4 69.7%; Okuda stage 2 65.7%, Okuda stage 3 18.0%). Due to the late stage of the disease at the time of presentation, 145 patients (59.2%) received palliative care only, 24 (9.8%) underwent liver resection, 38 (15.5%) liver transplantation and 38 (15.5%) chemotherapy. CONCLUSIONS: In this large single-centre series of HCC, the dominant contribution of HCV infection and chronic alcohol abuse as the underlying aetiology is documented. Diagnosis is usually made very late as reflected in the high proportion of patients in TNM stages 3 and 4 or Okuda stages 2 and 3. This resulted in a high percentage of patients who received palliative care only and very few who were eligible for treatment modalities with curative potential such as resection and liver transplantation.


Subject(s)
Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/etiology , Liver Cirrhosis/complications , Liver Cirrhosis/diagnosis , Liver Neoplasms/diagnosis , Liver Neoplasms/etiology , Adult , Age Distribution , Aged , Aged, 80 and over , Austria/epidemiology , Carcinoma, Hepatocellular/epidemiology , Comorbidity , Female , Humans , Incidence , Liver Cirrhosis/epidemiology , Liver Neoplasms/epidemiology , Male , Middle Aged , Probability , Retrospective Studies , Risk Factors , Sex Distribution , Survival Rate
9.
Am J Gastroenterol ; 94(11): 3336-40, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10566740

ABSTRACT

OBJECTIVE: We investigated the prevalence of hepatitis G-RNA (GBV-C/HGV-RNA), a recently cloned new flavivirus, and of antibodies to the envelope 2 antigen (anti-E2), a marker of past infection, in patients with autoimmune hepatitis, and compared it with the prevalence in patients with chronic viral hepatitis and healthy control individuals. METHODS: Sera of 63 patients with autoimmune hepatitis were studied for the presence of GBV-C/HGV-RNA by reverse-transcription polymerase chain reaction and for anti-E2 by enzyme-linked immunosorbent assay. GBV-C/HGV genotypes were determined by genome sequencing. RESULTS: Patients with autoimmune hepatitis had a similar high prevalence of GBV-C/HGV-RNA and anti-E2 antibodies as patients with chronic viral hepatitis B or C. GBV-C/HGV-RNA was found significantly more often in patients with autoimmune hepatitis (11%, p = 0.045), hepatitis B (16%, p = 0.004), or hepatitis C (21%, p = 0.001) than in healthy controls (2%). The prevalence of anti-E2 antibodies in patients with autoimmune hepatitis was not different from healthy controls (17% vs 13%, NS). The various subtypes of autoimmune hepatitis had similar prevalence rates of GBV-C/HGV-RNA as patients with liver-kidney microsomal antibody-positive hepatitis C. All of our anti-E2+ (GBV-C/HGV-RNA-) patients were positive for anti-smooth-muscle antibody, whereas only 29% of GBV-C/HGV-RNA+ (anti-E2-) patients were positive (p = 0.025). All seven of the GBV-C/HGV-RNA+ patients with autoimmune hepatitis had genotype 2a, which is also the most prevalent genotype in our region. CONCLUSION: The prevalence of GBV-C/HGV-RNA is significantly increased in patients with autoimmune hepatitis, compared with healthy controls, and is similar to the increased prevalence seen in chronic hepatitis B or C patients. Anti-E2 positivity was associated with antibodies against smooth-muscle antigen in all cases. All GBV-C/HGV+ autoimmune hepatitis patients were infected with genotype 2a.


Subject(s)
Antigens, Viral/analysis , Flaviviridae/genetics , Hepatitis, Autoimmune/virology , Membrane Glycoproteins/analysis , RNA, Viral/genetics , Viral Envelope Proteins/analysis , Adult , Aged , Aged, 80 and over , Antibodies/analysis , Antibodies, Viral/analysis , Enzyme-Linked Immunosorbent Assay , Female , Flaviviridae/immunology , Genotype , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/virology , Hepatitis C, Chronic/immunology , Hepatitis C, Chronic/virology , Hepatitis, Autoimmune/immunology , Humans , Kidney/immunology , Male , Microsomes/immunology , Microsomes, Liver/immunology , Middle Aged , Muscle, Smooth/immunology , Polymerase Chain Reaction , Prevalence , Sequence Analysis, RNA
10.
Wien Klin Wochenschr ; 110(19): 686-90, 1998 Oct 16.
Article in English | MEDLINE | ID: mdl-9823622

ABSTRACT

BACKGROUND: Hepatitis G (GBV-C/HGV) is an RNA-virus belonging to the flavivirus family and is capable of inducing hepatitis in rare cases. Its importance as a co-factor in the pathogenesis of liver disease needs to be clarified. AIMS: To determine the prevalence of HGV in chronic alcoholics with and without liver cirrhosis. PATIENTS: 86 alcoholics, 44 with liver cirrhosis and 42 without liver cirrhosis, were investigated; 93 healthy individuals served as controls. METHODS: Serum was tested for GBV-C/HGV-RNA by reverse-transcription polymerase chain reaction (RT-PCR) and for anti-E2, a marker of resolved GBV-C/HGV infection, by ELISA. GBV-C/HGV-RNA positive samples were sequenced and the GBV-C/HGV subtype determined. RESULTS: Eight out of 86 (9.3%) alcoholics were GBV-C/HGV-RNA positive, as compared to 2 out of 93 (2.2%) healthy controls (n. s.). Twenty-one (24.4%) alcoholics had anti-E2 in serum, whereas this antibody was found in 12 (12.9%) healthy persons only (n. s.). However, significantly more alcoholic patients (33.7%) than healthy controls (15.1%) had past or present contact with GBV-C/HGV (p = 0.006). 11.4% of alcoholic patients with liver cirrhosis and 7.1% of alcoholic patients without liver cirrhosis showed GBV-C/HGV-RNA. 34.1% of alcoholic patients with liver cirrhosis and 16.6% of alcoholic patients without liver cirrhosis had anti-E2. Among the 44 patients with liver cirrhosis, 8 out of 11 (72.7%) patients with variceal bleeding, but only 11 of 33 patients without bleeding had contact with GBV-C/HGV (p = 0.05). Seven out of 8 GBV-C/HGV-RNA positive alcoholics had genotype 2a, 1 had type 1a of GBV-C/HGV. CONCLUSION: Alcoholic patients have a significantly higher contact rate with GBV-C/HGV as compared to healthy controls. Alcoholics with liver cirrhosis tend to be more frequently infected than alcoholic patients without liver cirrhosis. A previous variceal bleeding episode is significantly associated with GBV-C/HGV infection.


Subject(s)
Flaviviridae , Hepatitis, Viral, Human/epidemiology , Liver Cirrhosis, Alcoholic/epidemiology , Liver Cirrhosis/epidemiology , Adult , Aged , Austria/epidemiology , Comorbidity , Cross-Sectional Studies , Female , Hepatitis, Viral, Human/diagnosis , Humans , Incidence , Liver Cirrhosis/diagnosis , Liver Cirrhosis, Alcoholic/diagnosis , Male , Middle Aged , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...